Literature DB >> 21924888

Does the presence of connective tissue disease modify survival in patients with pulmonary fibrosis?

V Navaratnam1, N Ali, C J P Smith, T McKeever, A Fogarty, R B Hubbard.   

Abstract

OBJECTIVES: Previous studies into the survival differences between individuals with idiopathic pulmonary fibrosis and those with connective tissue disease associated pulmonary fibrosis (CTD-PF) have yielded mixed results. The aim of this study is to compare the survival of individuals with CTD-PF to those with idiopathic pulmonary fibrosis clinical syndrome (IPF-CS) using data derived from The Health Improvement network, a large primary care database in the UK.
METHODS: Incident cases of CTD-PF and IPF-CS between the years 2000-2009 were identified. Survival analysis was performed using Kaplan-Meier methods, stratified by type of connective tissue disease. Cox regression was then used to compare mortality rates between the groups, adjusting for age, gender and year of diagnosis.
RESULTS: A total of 324 cases of CTD-PF and 2209 cases of IPF-CS were followed up over a mean period of 2.3 years. During this period, 113 (34.9%) cases of CTD-PF and 1073 (48.6%) cases of IPF-CS died. The mortality rates for cases with CTD-PF and IPF-CS were 123.6 per 1000 person years (95%CI: 102.8-148.9) and 229.8 per 1000 person years (95% CI: 216.4-244.0) respectively. After adjusting for age, sex and year of diagnosis, cases with CTD-PF had a better prognosis compared to those with IPF-CS (HR 0.76,95%CI: 0.62-0.92).
CONCLUSION: The prognosis of individuals with CTD-PF appears to be significantly better than those with IPF-CS, but remains an important cause of death in patients with connective tissue disease, and requires more effective treatment options.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21924888     DOI: 10.1016/j.rmed.2011.08.015

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  15 in total

1.  Clinical characteristics and survival in idiopathic pulmonary fibrosis and connective tissue disease-associated usual interstitial pneumonia.

Authors:  Esam H Alhamad
Journal:  J Thorac Dis       Date:  2015-03       Impact factor: 2.895

2.  Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease.

Authors:  Justin M Oldham; Cathryn Lee; Eleanor Valenzi; Leah J Witt; Ayodeji Adegunsoye; Scully Hsu; Lena Chen; Steven Montner; Jonathan H Chung; Imre Noth; Rekha Vij; Mary E Strek
Journal:  Respir Med       Date:  2016-11-04       Impact factor: 3.415

3.  Ten-Year Survival in Patients with Idiopathic Pulmonary Fibrosis After Lung Transplantation.

Authors:  Liesbeth ten Klooster; George D Nossent; Johanna M Kwakkel-van Erp; Diana A van Kessel; Erik J Oudijk; Ed A van de Graaf; Bart Luijk; Rogier A Hoek; Bernt van den Blink; Peter Th van Hal; Erik A Verschuuren; Wim van der Bij; Coline H van Moorsel; Jan C Grutters
Journal:  Lung       Date:  2015-09-24       Impact factor: 2.584

4.  Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.

Authors:  Tsutomu Hamada; Takuya Samukawa; Tomohiro Kumamoto; Kazuhito Hatanaka; Go Tsukuya; Masuki Yamamoto; Kentaro Machida; Masaki Watanabe; Keiko Mizuno; Ikkou Higashimoto; Yoshikazu Inoue; Hiromasa Inoue
Journal:  BMC Pulm Med       Date:  2015-09-30       Impact factor: 3.317

5.  Are risk predicting models useful for estimating survival of patients with rheumatoid arthritis-associated interstitial lung disease?

Authors:  Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho
Journal:  BMC Pulm Med       Date:  2017-01-13       Impact factor: 3.317

6.  Value of Serum Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen in Evaluating Severity and Prognosis of Connective Tissue Disease-Associated Interstitial Lung Disease.

Authors:  Qian Jin; Jisheng Zheng; Xianrong Xu; Yeming Hu; Ying Zhou; Weihua Xu; Feihua Huang
Journal:  Arch Rheumatol       Date:  2017-10-16       Impact factor: 1.472

7.  Myositis-specific Antibodies Identify A Distinct Interstitial Pneumonia with Autoimmune Features Phenotype.

Authors:  Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham
Journal:  Eur Respir J       Date:  2020-07-16       Impact factor: 16.671

Review 8.  Macrophage heterogeneity in respiratory diseases.

Authors:  Carian E Boorsma; Christina Draijer; Barbro N Melgert
Journal:  Mediators Inflamm       Date:  2013-02-27       Impact factor: 4.711

9.  Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes.

Authors:  Hanna M Nurmi; Minna K Purokivi; Miia S Kärkkäinen; Hannu-Pekka Kettunen; Tuomas A Selander; Riitta L Kaarteenaho
Journal:  BMC Pulm Med       Date:  2016-07-27       Impact factor: 3.317

Review 10.  Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights.

Authors:  Paola Faverio; Federica De Giacomi; Luca Sardella; Giuseppe Fiorentino; Mauro Carone; Francesco Salerno; Jousel Ora; Paola Rogliani; Giulia Pellegrino; Giuseppe Francesco Sferrazza Papa; Francesco Bini; Bruno Dino Bodini; Grazia Messinesi; Alberto Pesci; Antonio Esquinas
Journal:  BMC Pulm Med       Date:  2018-05-15       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.